Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Common Equity (2016 - 2025)

Sangamo Therapeutics has reported Common Equity over the past 16 years, most recently at -$14.3 million for Q4 2025.

  • Quarterly results put Common Equity at -$14.3 million for Q4 2025, down 162.66% from a year ago — trailing twelve months through Dec 2025 was -$14.3 million (down 162.66% YoY), and the annual figure for FY2025 was -$14.3 million, down 162.66%.
  • Common Equity for Q4 2025 was -$14.3 million at Sangamo Therapeutics, down from $6.2 million in the prior quarter.
  • Over the last five years, Common Equity for SGMO hit a ceiling of $469.4 million in Q1 2021 and a floor of -$14.3 million in Q4 2025.
  • Median Common Equity over the past 5 years was $184.3 million (2023), compared with a mean of $194.9 million.
  • Biggest five-year swings in Common Equity: increased 19.02% in 2021 and later tumbled 162.66% in 2025.
  • Sangamo Therapeutics' Common Equity stood at $375.3 million in 2021, then dropped by 21.42% to $295.0 million in 2022, then tumbled by 71.9% to $82.9 million in 2023, then plummeted by 72.53% to $22.8 million in 2024, then tumbled by 162.66% to -$14.3 million in 2025.
  • The last three reported values for Common Equity were -$14.3 million (Q4 2025), $6.2 million (Q3 2025), and $19.6 million (Q2 2025) per Business Quant data.